These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 27894107)

  • 1. Effect of Gonadal Hormones on Neurotransmitters Implicated in the Pathophysiology of Obsessive-Compulsive Disorder: A Critical Review.
    Karpinski M; Mattina GF; Steiner M
    Neuroendocrinology; 2017; 105(1):1-16. PubMed ID: 27894107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of gonadal hormones on periodicity of obsessive-compulsive disorder.
    Weiss M; Baerg E; Wisebord S; Temple J
    Can J Psychiatry; 1995 May; 40(4):205-7. PubMed ID: 7621390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fear extinction in an obsessive-compulsive disorder animal model: Influence of sex and estrous cycle.
    Reimer AE; de Oliveira AR; Diniz JB; Hoexter MQ; Miguel EC; Milad MR; Brandão ML
    Neuropharmacology; 2018 Mar; 131():104-115. PubMed ID: 29225044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder.
    Koo MS; Kim EJ; Roh D; Kim CH
    Expert Rev Neurother; 2010 Feb; 10(2):275-90. PubMed ID: 20136383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biological bases of obsessive-compulsive disorder].
    López-Ibor Aliño JJ; Viñas Pifarré R; Saiz Ruiz J
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1990; 18(5):306-15. PubMed ID: 1981298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
    Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
    Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mood-related obsessive-compulsive symptoms in a patient with bipolar affective disorder.
    Gordon A; Rasmussen SA
    J Clin Psychiatry; 1988 Jan; 49(1):27-8. PubMed ID: 3335487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder.
    Murphy DL; Zohar J; Benkelfat C; Pato MT; Pigott TA; Insel TR
    Br J Psychiatry Suppl; 1989 Dec; (8):15-24. PubMed ID: 2692636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications.
    Vlček P; Polák J; Brunovský M; Horáček J
    Pharmacopsychiatry; 2018 Nov; 51(6):229-242. PubMed ID: 28950396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin 2A receptor, serotonin transporter and dopamine transporter alterations in dogs with compulsive behaviour as a promising model for human obsessive-compulsive disorder.
    Vermeire S; Audenaert K; De Meester R; Vandermeulen E; Waelbers T; De Spiegeleer B; Eersels J; Dobbeleir A; Peremans K
    Psychiatry Res; 2012 Jan; 201(1):78-87. PubMed ID: 22285716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology.
    Korff S; Harvey BH
    Psychiatr Clin North Am; 2006 Jun; 29(2):371-90. PubMed ID: 16650714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conceptual and methodological issues in studies of obsessive-compulsive and Tourette's disorders.
    Hollander E; Liebowitz MR; DeCaria CM
    Psychiatr Dev; 1989; 7(4):267-96. PubMed ID: 2577300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental evidence for involvement of nitric oxide in low frequency magnetic field induced obsessive compulsive disorder-like behavior.
    Salunke BP; Umathe SN; Chavan JG
    Pharmacol Biochem Behav; 2014 Jul; 122():273-8. PubMed ID: 24780504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of animal models of obsessive-compulsive disorder: a focus on developmental, immune, endocrine and behavioral models.
    Grados M; Prazak M; Saif A; Halls A
    Expert Opin Drug Discov; 2016; 11(1):27-43. PubMed ID: 26558411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurobiology of childhood obsessive-compulsive disorder.
    Fitzgerald KD; MacMaster FP; Paulson LD; Rosenberg DR
    Child Adolesc Psychiatr Clin N Am; 1999 Jul; 8(3):533-75, ix. PubMed ID: 10442230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.
    Pittenger C; Krystal JH; Coric V
    NeuroRx; 2006 Jan; 3(1):69-81. PubMed ID: 16490414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A neural network of obsessive- compulsive disorder: modelling cognitive disinhibition and neurotransmitter dysfunction.
    Stein DJ; Ludik J
    Med Hypotheses; 2000 Aug; 55(2):168-76. PubMed ID: 10904436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis.
    McDougle CJ; Goodman WK; Leckman JF; Price LH
    Psychiatr Clin North Am; 1993 Dec; 16(4):749-66. PubMed ID: 8309811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamatergic dysfunction--newer targets for anti-obsessional drugs.
    Bhattacharyya S; Chakraborty K
    Recent Pat CNS Drug Discov; 2007 Jan; 2(1):47-55. PubMed ID: 18221217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder?
    Goodman WK; McDougle CJ; Price LH; Riddle MA; Pauls DL; Leckman JF
    J Clin Psychiatry; 1990 Aug; 51 Suppl():36-43; discussion 55-8. PubMed ID: 2199433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.